142 related articles for article (PubMed ID: 25337944)
1. The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma.
Zhang H; Jiao L; Cui S; Wang L; Tan J; Zhang G; He Y; Ruan S; Fan S; Zhang W
Int J Environ Res Public Health; 2014 Oct; 11(10):10991-1003. PubMed ID: 25337944
[TBL] [Abstract][Full Text] [Related]
2. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.
Barrington SF; Kettle AG; O'Doherty MJ; Wells CP; Somer EJ; Coakley AJ
Eur J Nucl Med; 1996 Feb; 23(2):123-30. PubMed ID: 8925845
[TBL] [Abstract][Full Text] [Related]
3. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods.
Yama N; Sakata K; Hyodoh H; Tamakawa M; Hareyama M
Ann Nucl Med; 2012 Jun; 26(5):390-6. PubMed ID: 22382609
[TBL] [Abstract][Full Text] [Related]
5. A practical individualized radiation precaution based on the dose rate at release time after inpatient 131I ablation therapy.
Han S; Jin S; Yoo SH; Lee HS; Lee SH; Jeon MJ; Ryu JS
PLoS One; 2021; 16(5):e0251627. PubMed ID: 34019555
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
7. Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy.
Kusakabe K; Yokoyama K; Ito K; Shibuya H; Kinuya S; Ito M; Higashi T; Togawa T; Koizumi K; Yoshimura M; Uchiyama M; Okamoto T; Kanaya S; Kanaya K; Yoneyama T; Ikebuchi H; Yanagida S; Shibata K; Segawa K; Yamamoto A
Ann Nucl Med; 2012 May; 26(4):370-8. PubMed ID: 22450825
[TBL] [Abstract][Full Text] [Related]
8. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
9. Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management.
Li P; Zhang A; Liu Y; Xu C; Tang L; Yuan H; Liu Q; Wang X; Feng D; Wang L; Huang G; Song S
Thyroid; 2019 Jan; 29(1):93-100. PubMed ID: 30351248
[TBL] [Abstract][Full Text] [Related]
10. Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure.
Gabriel S; Farman-Ara B; Bourrelly M; Carpentier O; Sebag F; Palazzo FF; De Micco C; Mancini J; Henry JF; Mundler O; Taïeb D
Nucl Med Commun; 2011 Sep; 32(9):829-33. PubMed ID: 21633315
[TBL] [Abstract][Full Text] [Related]
11. [A study on the isolation period of patients with metastatic thyroid cancer treated by 131I according to a new guideline].
Tsuchimochi S; Nakajo M; Umanodan T; Fukushima N; Shigaki S; Kiku T
Kaku Igaku; 2001 Nov; 38(6):747-54. PubMed ID: 11806086
[TBL] [Abstract][Full Text] [Related]
12. Thyroid remnant ablation with 1110MBq of 131I in outpatients: measurement of effective dose to household members and establishment of safety precautions.
Yoshimura M; Tsutsui H; Ikeda N; Koizumi K
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):101-8. PubMed ID: 23474638
[TBL] [Abstract][Full Text] [Related]
13. Measurements and prediction of the ambient dose rate from patient receiving radioiodine administration after thyroid ablation.
Kim CB; Jung JW; Jeong KH; Ahn BC; Lee HH; Lee J
Radiat Prot Dosimetry; 2012 Aug; 151(1):158-61. PubMed ID: 22171099
[TBL] [Abstract][Full Text] [Related]
14. Hospital discharge policy in thyroid cancer patients treated with 131I: the effect of changing from fixed time to exposure rate threshold.
Mohammadi H; Saghari M
Health Phys; 1997 Mar; 72(3):476-80. PubMed ID: 9030851
[TBL] [Abstract][Full Text] [Related]
15. Management of 131I therapy for thyroid cancer: cumulative dose from in-patients, discharge planning and personnel requirements.
Pacilio M; Bianciardi L; Panichelli V; Argirò G; Cipriani C
Nucl Med Commun; 2005 Jul; 26(7):623-31. PubMed ID: 15942483
[TBL] [Abstract][Full Text] [Related]
16. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
17. Radiation dose rates of differentiated thyroid cancer patients after
Jin P; Feng H; Ouyang W; Wu J; Chen P; Wang J; Sun Y; Xian J; Huang L
Radiat Environ Biophys; 2018 May; 57(2):169-177. PubMed ID: 29525896
[TBL] [Abstract][Full Text] [Related]
18. Thyroid cancer patients treated with 131I: radiation dose to relatives after discharge from the hospital.
Rémy H; Coulot J; Borget I; Ricard M; Guilabert N; Lavielle F; Camps E; Baudin E; Lumbroso J; Leboulleux S; Schlumberger M
Thyroid; 2012 Jan; 22(1):59-63. PubMed ID: 22136157
[TBL] [Abstract][Full Text] [Related]
19. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation.
Han YH; Jeong HJ; Sohn MH; Lee SY; Lim ST
Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):124-130. PubMed ID: 29521481
[TBL] [Abstract][Full Text] [Related]
20. Influence of 131I diagnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the impairment of successful ablation.
Hu YH; Wang PW; Wang ST; Lee CH; Chen HY; Chou FF; Huang YE; Huang HH
Nucl Med Commun; 2004 Aug; 25(8):793-7. PubMed ID: 15266173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
